Evidence map›Paper›PMID 34344758›Full record

ArticleCancer discovery2021

Chemerin Tips the Scales in ccRCC to Evade Ferroptosis.

Ed Reznik, Hui Jiang, A Ari Hakimi

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. MJournal of ovarian research · 2025
    Article
  2. Article
  3. mOncogene · 2024
    Article
  4. Article
  5. Roles of ferroptosis in urologic malignancies.Cancer cell international · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ed ReznikComputational Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6511-5947
Hui JiangUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. hakimia@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is both a risk factor for the development of the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC), and a prognostically protective factor for clinical outcomes. In this issue of

Indexed as

Carcinoma, Renal CellFerroptosisKidney NeoplasmsAdipose TissueHumansLipid Metabolism

Identifiers

PMID34344758
OpenAlexW3190587042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.